SCHEMBL8962396

SCHEMBL8962396

CCCCCCCCCCCCSC(=O)CS(=O)(=O)Nc1ccc(F)cc1F

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
SOAT1 P35610 1/20 0.41
TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9321851 0.74 KMT2A (0.55) KMT2A
SCHEMBL856209 0.74 CYP3A4 (0.57) KMT2A
SCHEMBL9651520 0.73 KMT2A (0.51) KMT2A
SCHEMBL7574611 0.72 PKM (0.52) SOAT1
SCHEMBL9061498 0.71 TRPV1 (0.38) SOAT1TRPV1
SCHEMBL8962527 0.71
SCHEMBL8962355 0.71
SCHEMBL8962505 0.71
SCHEMBL8962767 0.71
SCHEMBL8962555 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996019446-A1 β-CARBOXY SULFONAMIDE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1996-06-27 WO claimed
US-5491170-A TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-02-13 US claimed